← 返回

A2AR 限制 IL-15 诱导的高细胞毒性 CD39(+) NK 细胞的生成

英文原题:A2AR limits IL-15-induced generation of CD39(+) NK cells with high cytotoxicity.

查看英文原题

A2AR limits IL-15-induced generation of CD39(+) NK cells with high cytotoxicity.

PubMed 2022/12/16(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD39介导的NK细胞活性抑制已被证实,但人类CD39+ NK细胞的特征尚不清楚。我们研究了人循环CD39+ NK细胞的特征。在健康供者中,循环CD39+ NK细胞占总NK细胞的比例相对低于CD39- NK细胞。尽管如此,CD39+ NK细胞中表达CD107a的比例更高。同样,在乙型肝炎病毒患者或肝细胞癌患者中,CD39+ NK细胞中表达CD107a的比例也更高。用NK敏感的K562细胞或白细胞介素(IL)-12/IL-18刺激后,相对于CD39- NK细胞,CD39+ NK细胞表达更高水平的CD107a、IFN-γ和TNF-α。

重要的是,IL-15诱导了CD39+ NK细胞的生成。相反,A2A腺苷受体(A2AR)连接通过抑制IL-15信号传导抑制了CD39+ NK细胞的生成。这些数据首次证明,A2AR拮抗IL-15诱导的人CD39+ NK细胞生成,而CD39+ NK细胞比CD39- NK细胞具有更强的细胞毒性。IL-15诱导的人CD39+ NK细胞可能是基于NK细胞过继转移免疫治疗的更好选择。

展开英文摘要原文

CD39-mediated inhibition of natural killer (NK) cell activity has been demonstrated, but the characteristics of CD39 + NK cells in humans are not known.

We investigated the characteristics of human circulating CD39 + NK cells. In healthy donors, the proportion of circulating CD39 + NK cells in total NK cells was relatively low compared with that of CD39 - NK cells. Nonetheless, a higher proportion of CD39 + NK cells expressed CD107a.

Similarly, a higher proportion of CD39 + NK cells expressed CD107a in patients with hepatitis B virus or patients with hepatocellular carcinoma. Stimulation with NK-sensitive K562 cells or interleukin (IL)-12/IL-18 activated CD39 + NK cells to express higher levels of CD107a, IFN-γ and TNF-α, relative to CD39 - NK cells.

Importantly, IL-15 induced the generation of CD39 + NK cells. In contrast, A2A adenosine receptor (A2AR) ligation suppressed the generation of CD39 + NK cells by inhibiting IL-15 signaling. These data for the first time demonstrated that A2AR counteracts IL-15-induced generation of human CD39 + NK cells, which have a stronger cytotoxicity than CD39 - NK cells. IL-15-induced human CD39 + NK cells might be better choice for immunotherapy based on adoptive transfer of NK cells.

论文信息

作者
Kang G、Zhao X、Sun J、Cheng C、Wang C、Tao L、Zong L、Yin W
第一作者单位
School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China.China
通讯作者单位
School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China. Electronic address: wangxuefu@ahmu.edu.cn.China
期刊
International immunopharmacology2023 Jan
原文标识
PubMed 36529024 · DOI 10.1016/j.intimp.2022.109567